Key Takeaways:
Shares of uranium producer Cameco Corp. plunged nearly 6% in the latest trading session, a sharp reversal from recent gains and a stark contrast to a new "Outperform" rating from William Blair initiated just one day prior.
"Despite a lofty P/E near 100, the company's PEG ratios and 114% EPS growth support a buy-on-dip strategy below $120," one Seeking Alpha analyst wrote recently, highlighting the valuation tension in the stock.
Cameco (NYSE:CCJ) closed at $116.61 on Tuesday, a 5.67% decline that trailed the S&P 500's modest 0.64% loss. The move comes after the stock had rallied 17.1% over the past month, far outpacing the broader market. The sell-off places the stock just below a key technical level, with some analysts suggesting a buying opportunity under $120 for the world's largest publicly traded uranium producer.
The divergence between the stock's sharp one-day drop and bullish analyst sentiment underscores the debate over Cameco's valuation. With a forward P/E ratio of 78.64, it trades at a significant premium to the industry average of 16.02. Investors are weighing this rich valuation against the company's central role in the resurgent nuclear energy sector, with full-year earnings expected to grow over 52% to $1.57 per share.
The timing of the sell-off is notable, coming just a day after William Blair initiated coverage on Cameco with an "Outperform" recommendation on April 20. Fintel data shows the average one-year price target for Cameco stands at $165.55, representing a potential 33.92% upside from its closing price on April 15. However, Zacks currently holds a #4 (Sell) rating on the stock, pointing to the division among analysts.
Cameco is widely seen as a primary vehicle for investors to gain exposure to the growing demand for nuclear power. The company's high-grade uranium mines in Canada and global contracts position it as a leader. Proponents point to the global push for decarbonization and energy security as long-term tailwinds for uranium demand, which could support Cameco's earnings growth and justify its premium valuation. The company is scheduled to release its next earnings report on May 5, 2026, which will be a key test of this thesis.
This article is for informational purposes only and does not constitute investment advice.
